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ABSTRACT: Nanoparticle morphology (size, shape, and composition) and surface chemistry
are the determining factors underpinning the efficacy of such materials in therapeutic
applications. The size, shape, and surface chemistry of a nanoparticle can strongly influence
key properties such as interactions with diverse biological fluids and interfaces and, in turn,
impact the delivery of bioactive cargo, modulating therapeutic performance. This is
exemplified in ocular drug delivery, where potential therapeutics must navigate complex
biological media such as the gel-like vitreal fluid and the retina. Biodegradable block copolymer
amphiphiles are a robust tool for the engineering of various types of self-assembled
nanoparticles with diverse morphologies ranging from spherical and tubular polymersomes to
spherical and worm-like micelles. Here, we explore the effect of morphological features such as
shape and surface chemistry upon the interactions of a series of copolymer nanoparticles with
retinal (ARPE-19) cells and the release of a low solubility drug (dexamethasone) that is
currently used in ocular therapy and study their diffusion in vitreous using ex vivo eyes. We
demonstrate that both aspect ratio and surface chemistry of nanoparticles will influence their
performance in terms of cell uptake, drug release, and diffusion with high aspect ratio shapes demonstrating enhanced properties in
relation to their spherical counterparts.
■ INTRODUCTION
The important role of nanoparticle morphology for perform-
ance of such synthetic materials in a biological context is a
well-established concept.1 Greater understanding of the
influence that certain morphological features (such as size,
shape, and composition) can have upon complex biological
interactions, and associated properties such as drug release, will
aid in developing design principles to engineer next-generation
nanotechnologies that might overcome current limitations in
the field.1−3 However, due to the inherent heterogeneity of
biology (not only at the level of organs and tissues but also
with respect to cell types and subcellular systems), there
cannot be a “one-size-fits-all” approach to nanomedicine.4,5
The impact of nanoparticle morphology may well be quite
different depending upon the niche application and biological
context, which necessitates customized in vitro and in vivo
assays to provide specific insights toward the target.6−8
Ocular therapy (in contrast to areas such as neurological or
immunological therapy) possesses a host of unique biological
challenges peculiar to the biology of the eye.9 Drug
administration to the eye is complicated, especially when the
posterior segment has to be targeted. Neither topical (eye
drops) nor systemic treatments effectively reach the back of
the eye due to significant ocular barriers such as the blood−
retinal barrier or the natural elimination processes. This is
usually overcome using intravitreal injections, an unpleasant
procedure that could be lessened by the development of
controlled release technology, increasing the interval between
treatments.10−12 In terms of disease specifics, a condition like
age-related macular degeneration (AMD) is a worldwide
disease that is on the rise in an aging population.13 AMD is
now a top ten priority for the World Health Organization
(WHO), and patient numbers are expected to reach 288
million by 2040, motivating the development of new
treatments.14,15 AMD is caused by age-related degeneration
of retinal pigmented epithelium (RPE) cells in the central
region of the retina (the macula) that can lead to accumulation
of extracellular material and inflammation.16 Intravitreal
injection is the only appropriate treatment modality that
exists, which requires a good understanding of how drug
delivery is affected by the vitreous in which the administration
takes place. The vitreous fluid within the eye is a complex
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medium, accounting for 80% of the eye volume, which
comprises collagen fibers and hyaluronic acid, making it a gel-
like, viscous liquid.17 In addition, the inner limiting membrane
(ILM) of the retina forms a physical barrier for drug delivery to
retinal cells.
Nanoparticle morphology has been shown to significantly
influence properties such as circulation times, cell interactions,
and flow behavior.18−22 In terms of ocular therapy, particle
surface charge has been shown to influence permeation in the
vitreous, with positive charge-bearing particles showing
enhanced diffusion without crossing the inner retinal
membrane.10,23−25 In contrast, neutral and negatively charged
macromolecules and nanoparticles showed some permeation
across the inner limiting membrane, demonstrating a possibly
enhanced delivery to cells.10,24,25 The potential of nano-
particles to impact drug delivery, particularly in ocular therapy,
is highly appealing, and morphology has a key role in realizing
this.
The anti-inflammatory corticosteroid, dexamethasone
(DEX), is a frontline therapeutic for ocular therapy. As with
many drug molecules, DEX has poor water solubility owing to
its hydrophobic nature, which limits administration to the
retina at doses necessary for effective therapy (ca. 150 μg/mL
over 2 months).26 Without formulation, DEX must be given as
an aggregated suspension that provides rapid drug release and
necessitates daily intravitreal injection. Current strategies to
improve DEX delivery include intravitreal implants (e.g.
Ozurdex, Allergan) that can provide sustained release for 6
months.27 However, this implant previously showed unwanted
complications such as movement from the back to the front
segment of the eye, affecting vision, which therefore requires
surgical removal.28 This opens an opportunity for nano-
medicine to provide a competitive solution.10 In general, the
design of nanoparticles, particularly those comprising bio-
degradable copolymers, for application in ocular therapy is an
unexplored area.
Here, we explore the key properties of a range of
nanoparticle morphologies comprising biocompatible, amphi-
philic block copolymers in relation to cell viability and uptake,
drug (DEX) release, and diffusion in vitreous. Based on
previously reported systems, we utilized spherical and worm-
like micelles, comprising poly(ethylene glycol) (PEG) and
combinations of poly(trimethylene carbonate) (PTMC) and
poly(ε-caprolactone) (PCL), as well as spherical and tubular
polymersomes, comprising PEG and poly(D,L-lactide)
(PDLLA).29−32 Using a range of physical characterization
techniques and biological assays, we demonstrated that particle
shape and composition have a significant effect upon
performance to direct cellular interactions, control drug
release, and enhance diffusion in vitreous (using an ex vivo
eye model). Overall, our findings highlight the value of high
aspect nanoparticles such as tubes and worms and the potential
for nonspherical particles to improve the performance of
nanotherapeutics. To the best of our knowledge, this is the first
report that systematically compares the biological impact of
such diverse morphologies arising from copolymer self-
assembly. In these terms, our findings will not only be of use
for ocular delivery but for broader therapeutic applications of
such nanomaterials.
■ MATERIALS AND METHODS
Materials. All chemicals were used as received unless otherwise
stated. PEG initiators were purchased from Rapp Polymere GmbH
(Germany) and JenKem Technology (United States). Fluorescent
BDP-FL-COOH was supplied by Lumiprobe. All other chemicals
were supplied by Sigma-Aldrich (Merck). Porcine eyes were supplied
by Lassa slaughterhouse (Finland). Vitreal fluid was collected from
porcine eyes as reported in the literature.33 Ultrapure Milli-Q water
was obtained from a Labconco Water Pro PS purification system
(18.2 MΩ) and used for all aqueous solutions. ARPE-19 cells and
related medium were obtained from ATCC/LGC Standards. Details
of all instrumentation used for particle characterization can be found
in the Supporting Information.
Polymer Synthesis and Nanoparticle Formulation. Polymer
synthesis and particle fabrication were conducted as previously
described.30,31 Reaction schemes and polymer characterization data
can be found in Figures S1−4. Fluorescent polymers were prepared
by conjugation with Bodipy-FL-CO2H dye via esterification (Figure
S5). The resulting nanoparticles were characterized using a
combination of AF4, DLS, and CryoTEM. Addition of charge-bearing
block copolymers was performed by mixing either amino (A)-
modified or carboxylic acid (CA)-modified copolymer with
unmodified (U)-copolymer at 10 wt % ratio (Figures S1 and S2).
For confocal imaging, fluorescent particles with equivalent sizes were
obtained by mixing BODIPY-copolymer with unmodified polymer at
10 or 50 wt %, respectively, for micellar or vesicular systems
(equivalent to 0.1 or 0.5 mg/mL of dye-labeled polymer for a total
polymer mass of 1 mg/mL).
Drug Encapsulation. The hydrophobic corticosteroid dexa-
methasone (DEX) was used in this study. DEX loading of particles
was presented in terms of total mass in relation to the mass of the
copolymer. For polymersomes, encapsulation efficiency was deter-
mined using UPLC. Two hundred microliters of particles was
evaporated in a 1 mL Eppendorf tube using a vacuum centrifuge for 2
h at 60 °C. The dried powder was subsequently dissolved in a 1:40
mix of THF:ACN, and any undissolved matter was removed by
centrifugation at 6 krcf for 10 min (DEX dissolves in this solvent
mixture). The supernatant solution (containing DEX) was diluted
50% with Milli-Q water and analyzed with UPLC using a ACQUITY
HSS T3 column (100 Å, 1.8 μm, 2.1 × 50 mm, C18) at a flow rate of
0.01 mL/min with elution peaks appearing at 0.73 min for all
measurements (conducted in triplicate). Drug encapsulation









For micellar morphologies, encapsulation efficiency was determined
using UV−visible spectroscopy. Ten microliters of a polymer stock
was hydrated (as nanoparticles) into PBS, and 10 μL of the same
stock was dissolved in ACN. The sample dissolved in organic solvent
was considered the reference, containing 100% of DEX (no self-
assembly occurred in the reference solvent). Nanoparticle solutions in
PBS were filtered (0.2 μm PES filter), and 500 μL was transferred to a
5 mL Eppendorf tube and freeze-dried overnight. After drying, 1 mL
of a 1:1 mixture of ACN:water was added, and the resulting solution
was centrifuged to remove undissolved salts. The supernatant was
then diluted 4 times before measuring the absorbance of DEX at 240
nm. DEX concentration was calculated from a DEX calibration curve
in the same solvent (y = 14.41x with R2 = 0.999). Samples hydrated
by PBS ([DEX]PBS) were compared with samples in organic solvent
([DEX]ACN) as a reference (Figure S11). Drug loading efficiencies









Drug Release. Drug release studies were performed using a Rapid
Equilibrium Dialysis (RED) device with 8K MWCO inserts as
supplied by Thermo Fisher Scientific. The donor chamber contained
250 μL of sample and 250 μL of buffer (with 25 μL premixed Pen-
Strep antibiotic). The receiving chamber contained 750 μL of PBS.
Aliquots of 100 μL were extracted from the receiving chamber at
specific time points, and 100 μL of PBS was pipetted in replacement
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to maintain sink conditions. To each aliquot, 400 μL of acetonitrile
was added to dilute the sample and precipitate any salts prior to
centrifugation at 6 krcf for 10 min. Fifty microliters of supernatant was
then withdrawn and dissolved in Milli-Q water at a 1:1 volume ratio.
Each of three replicates was measured by UPLC (dilution factor 10)
to determine the [DEX]. The cumulative release of DEX (%) was
calculated as follows, with [DEX]t the measured concentration at time
t and 12.5 the dilution factor (total volume of 1250 μL/sample
volume 100 μL), where Mt is mass of drug in the device, and Qt is
cumulative mass of drug released:
= [ ] × ×M ( DEX 0.1 mL) 12.5t t
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Cell Assays. ARPE-19 cells were cultured at 37 °C in 5% CO2
using DMEM:F12 medium. Cells were plated at 2 × 105 cells per well
and treated with nanoparticle formulations at 3 different polymer
concentrations (1.25, 0.625, and 0.250 mg/mL) for 24 h. After
incubation with particles, cells were washed several times with DPBS.
To measure health, cells were treated with 10% Alamar Blue solution
and incubated for 4 h, and the absorbance at 570 nm was recorded
thereafter. To measure proliferation, cells were incubated for 3 days
without particles. Thereafter, 10 μL per well of CCK-8 solution was
added, and microplates were incubated for an additional 3 h before
absorbance was read at 450 nm.
Cellular Uptake Assays. ARPE-19 cells were plated on either 24-
well plates or special glass coverslips at 2 × 105 cells per well and
treated with 1 mL of fluorescently labeled nanoparticles in
DMEM:F12 at 1 mg/mL for 24 h. After incubation, cells were
washed several times with DPBS and processed using either flow
cytometry or confocal microscopy.
For flow cytometry, 1 mL of medium was added per well together
with 5 μg/mL of Hoechst 33342 nuclear stain. After 30 min of
incubation, cells were washed 3 times with DPBS, trypsinized, and
resuspended in DPBS. The resulting cell suspensions were transferred
to FACS tubes for analysis. For confocal microscopy, cells were fixed
by incubation using 1 mL per well of 4% paraformaldehyde solution
in DPBS for 15 min. Once washed, staining was achieved using 300
μL of 0.2% Triton in DPBS per well for 10 min, followed by 3 DPBS
rinses and addition of 300 μL of Phalloidin 568 per well. After 45 min,
5 washing steps using 500 μL of TWEEN solution per well (0.2% in
DPBS) were performed, waiting 5 min between repeats. Finally, cells
were rinsed with DPBS, treated with 300 μL of DAPI solution per
well for 5 min, and rinsed before imaging.
Mobility Studies in Vitreous Using ex Vivo Eyes. Mobility
studies of nanoparticles in vitreous were performed using porcine eyes
ex vivo.34 To prepare the eyes, they were cleaned from muscles,
nerves, and all other undesired tissues. Freshly prepared eyes were
briefly dipped into 70% ethanol and then stored in PBS at 4 °C
overnight. Thereafter, eyes were cut circumferentially below the
limbus to remove the anterior section, including iris and lens. A 30G
syringe was used to inject (in the fresh eye vitreous) 50 μL of
fluorescent nanoparticles at a polymer concentration of 0.25 mg/mL.
Next, the cut surface was covered with a microwell dish (MatTek
Corporation, Ashland, MA, United States), avoiding air bubbles
between the vitreous and the glass window. The eye cup was then
inverted to place the window surface facing down for imaging.
The key parameter for mobility evaluation was the ratio of particle
diffusion coefficient (as described in the Stokes−Einstein equation) in
water (DW) compared to that in vitreous (DV): Dw/DV (Figure S13).
DW was calculated at 37 °C in water, using DLS. To compensate for
the inaccuracies relating to the hydrodynamic radius of tubular
polymersomes, approximations based on the diffusion of rod-like
particles were used rather than standard calculations based upon
spherical shapes.35 Mobility of particles in vitreous fluid was recorded
as a movie with 50 ms temporal resolution, and particles were tracked
using single particle tracking technique. From the videos, the mean
square displacement (MSD) value was computed using the @
MSDanalyzer MATLAB plugin in Imaris 9.2 software based on the
equation MSD(Δt) = 4DVΔt for 2D particle tracking (Figure
S13B).33
Retinal Explant Preparation and Immunohistochemistry.
Fresh bovine eyes were obtained from a local slaughterhouse (Eastern
Finland), and the retinal explants were prepared according to a
published method.36 Surrounding connective tissues were removed,
and the eye was dipped shortly in 20% ethanol. To expose the neural
retina in the posterior segment, first, the eyeball was bisected and the
anterior segment was discarded followed by vitreous removal. Next,
the eye cup was filled with CO2 independent medium (Gibco,
Thermo Fisher Scientific, United States) and cut by scissors to make
four flaps. Circular section of the retina was isolated using a tissue
puncture blade, and two explants were placed on a 75 mm Transwell
insert where the explant was nourished by culture medium
(Neurobasal-A, 2% B-27 supplement, 2% penicillin−streptomycin,
1% L-glutamine; all Gibco, Thermo Fisher Scientific, United States).
Ten microliters of Bodipy-FL-labeled CA-tubes (3 mg/mL) was
placed gently on top of the explant and incubated for 24 h at 37 °C
with 5% CO2. The next day, the medium was replaced with 4%
paraformaldehyde (PFA) to fix the retinal explant. After 2 h of
incubation at 4 °C, PFA was removed and replaced by 30% sucrose in
PBS and incubated overnight at 4 °C. Retinal explants were snap
frozen in O.C.T (Tissue-Tek Sakura) using liquid nitrogen.
Cryosections (16 μm) were obtained by cutting from four different
area of the explant with cryostat (Leica CM3050s). Retinal sections
were incubated in 50 μL of blocking solution (5% goat serum) for 1 h
at RT followed by overnight incubation with rabbit antibody against
Collagen IV (1:200) (ab6586, Abcam, United States) at 4 °C to tag
the ILM. The next day, sections were stained with secondary antibody
(Alexa Fluor 568-labeled goat antirabbit secondary antibody, A11036,
Thermo Fisher Scientific, OR, United States) and Hoechst at 10 μg/
mL concentration (33342, Invitrogen, Thermo Fisher, United States)
for 1 h at RT. Lastly, retinal sections were covered with mounting
medium (Vectashield, Vector Laboratories, CA, United States) and
kept at 4 °C until imaging. Sections were imaged with a confocal
microscope (Leica TCS SP8) using 20× (HC PL APO) and 93×
(HC PL APO) objectives.
■ RESULTS AND DISCUSSION
To engineer various nanoparticle morphologies, we synthe-
sized a range of well-defined block copolymers comprising
PEG, PTMC, PCL, and PDLLA in various combinations, using
procedures presented in our previous reports (Figures S1−
S5).29−32 To enable further study into the impact of surface
chemistry upon performance, copolymers with PEG-terminal
amine (A) and carboxylic acid (CA) moieties were also
prepared and blended with unmodified (U) polymers for
assembly into A- and CA-bearing particles. Spherical and
tubular polymersomes were fabricated using our protocols
where 10 wt % of A or CA groups could be stably
incorporated, yielding particles with sizes around 450 (U/A)
or 250 nm (CA) (Figures S6). Zeta potentials of U/CA-
spheres or -tubes were ≈−45 mV and those of A-spheres/
tubes were ≈−25 mV owing to the presence of surface amine
moieties amidst PEG polymers. Spherical and worm-like
micelles were fabricated using our protocols where 10 wt %
of A or CA groups could be stably incorporated with sizes ≈30
nm for spherical and ≈150 nm for worm-like micelles. Zeta-
potentials of spherical U/CA-micelles were approximately −5
mV, whereas for A-micelles they were ≈4 mV; values for U/
CA-worms amounted to −17 mV and A-worms ≈7 mV
(Figure S7). Particle sizing was conducted using DLS, with the
elongated particle (tube or worm) diameter calculated as if it
was spherical (based on Stokes−Einstein equation), and cryo-
TEM imaging provided detailed structural features of these
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diverse nanoparticles (Figures 1A and S8). High aspect ratio
structures (tubes and worms) possess lengths >1 μm and
widths of around 100 or 50 nm, respectively.
Using a retinal pigmented epithelial cell line (ARPE-19), no
significantly detrimental effect was observed upon cell viability
or proliferation using Alamar blue and CCK-8 assays,
respectively, arising from treatment with any of the nano-
particle candidates (Figure 1B). Interestingly, some reduction
in viability was observed in cell proliferation after treatment
with tubes and worms at lower concentrations (to a minimum
of 80%), but this did not bear out at higher concentrations and
was not of sufficient magnitude to be of concern. Using
confocal microscopy and flow cytometry, cellular uptake was
confirmed in each case (Figure 2A and B, S9, and S10).37
Overall, tubes were more readily taken up by cells as compared
to their spherical counterparts by ca. 20% (Figure 2A). In
terms of surface composition, it was clear from flow cytometry
results that A-spheres/tubes were less readily taken up. This
result was somewhat counterintuitive as the introduction of
positive charge on the nanoparticle surface should induce a
favorable interaction with the negatively charged plasma
membrane.38 In our system, this difference was related to the
tendency of amine-modified spheres/tubes to bind to and
aggregate on the cell membrane, hindering efficient internal-
ization (evidenced in Figure S9C/Videos 1−6). Uptake of U-
and CA-tubes was optimal in terms of the relative number of
cells that contained nanoparticles (as presented in flow
cytometry data). In contrast, there was a strong difference
between the uptake of spherical and worm-like micelles with
almost twice the number of cells containing worms (Figure
2B). In this case, there was no significant impact arising from
surface composition, and all three worm systems showed
increase cell uptake. This distinct uptake behavior was likely
caused by the enhanced diffusive properties of high aspect ratio
structures, which was more intense in the case of worms due to
their greater length:width aspect ratio as compared to that of
tubes.
Another important property of such nanoparticles is their
ability to release encapsulated drug, and the effect that their
unique morphologies have on this property has not yet been
explored. There were key distinctions, in terms of drug loading,
between nanoparticles under examination. PEG−PDLLA
polymersomes, formed via solvent switch and (in the case of
tubes) with dialysis-induced shape transformation possessed a
low loading of DEX at around 0.5 wt % (yielding a total
concentration of ca. 25 μg/mL, see Supporting Information).
In contrast, micellar technology was capable of higher drug
loadings at up to 4 wt % (spherical micelles) or 10 wt %
(worm-like micelles) owing to the molecular structure of
PEG−PTMC/PCL copolymers and the direct hydration
process, yielding total concentrations of 180 and 500 μg/mL,
respectively (Figure S11). Release of DEX from polymersomes,
diluted using vitreous liquid, proceeded under first order
kinetics. In contrast to free drug, which rapidly equilibrated
across the system within 6 h (k1 = 0.55 h
−1, Figure S12A),
release from polymersomes was slowed, albeit with a distinct
impact arising from shape upon the rate constant (Figures 2C
and S12B). In each case there was a 20−30% reduction in the
rate constant of drug release in the tubular as compared to
spherical polymersomes. In terms of release from the micellar
Figure 1. Biocompatible block copolymer nanoparticles and their effect on retinal (ARPE-19) cells. (A) Cryo-TEM images of unmodified
polymersomes, tubes, micelles, and worms (left to right, scale bars = 0.2 μm). Images of nanoparticles with different surface compositions available
in Figure S8. (B) Relative proliferation (CCK-8) and health (Alamar Blue) values of retinal cells after 24 h incubation with increasing
concentrations of diverse nanoparticles with unmodified (U), 10% amine-modified (A), or 10% carboxylic acid-modified (CA) surfaces.
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particles, although spherical micelles exhibited first order
release, comparable to that from tubular polymersomes, a
striking difference was observed when studying worm-like
morphologies (Figures 2D and S12C). DEX release from
worms did not follow first order kinetics but could be fitted
using the Korsmeyer−Peppas approximation with values for
the release exponent (n) similar to those reported for drug-
loaded liposomes that was diffusion limited (n = 0.2−0.3).39,40
Release from 10 wt % loaded worms with various surface
compositions (U/A/CA) was comparable and proceeded to
full release over 3 days (as compared to ca. 10 h with spherical
micelles). In part, this observed difference was attributed to the
higher loading of DEX in worms and the concomitant
(relative) reduction in drug efflux as [DEX]worms >
[DEX]solubility. Reducing the loading of DEX in worms
highlighted this property, where 8 and 6 wt % worms showed
a reduction in the release exponent and an increase in the rate
constant, highlighting faster release when [DEX]worms ≈
[DEX]solubility. Overall, high aspect ratio nanoparticles, by
definition nonspherical, demonstrated their capacity to reduce
the rate of drug release; for worm-like micelles, with higher
loading content of drug, this was even significantly enhanced.
Following on from in vitro studies, we explored the impact of
particle shape and surface chemistry on mobility in the vitreous
using ex vivo porcine eyes, an excellent model system due to
similarity to the human eye.41 After addition to a prepared eye,
fluorescent nanoparticles with Bodipy-FL dye were tracked as
they underwent diffusion within the gel-like vitreous fluid.
Particle mobility was quantified using the ratio of diffusion
coefficients (Dw/Dv) measured in water (Dw, using the
Figure 2. Effect of nanoparticle morphology upon uptake in retinal (ARPE-19) cells and the release of a low solubility drug (dexamethasone).
Uptake of (A) spherical and tubular polymersomes and (B) spherical and worm-like micelles into cells as quantified using flow cytometry
accompanied by confocal microscopy (cytoplasm = red, nucleus = blue, nanoparticles = green, and scale bars = 10 μm). (C) Cumulative release of
DEX from spherical (black) and tubular polymersomes (blue) fitted using first-order kinetics (full analysis on all polymersome samples available in
Figure S12). (D) Cumulative release of DEX from spherical (black) and worm-like micelles (blue) fitted using first-order and Korsmeyer−Peppas
kinetics, respectively (full analysis on all micelle samples is available in Figure S12).
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Stokes−Einstein equation) compared to that measured in
vitreous fluid (Dv, extracted from mean-squared displacement,
MSD) as described in the methods.33 MSDs of particles were
calculated from tracked trajectories to provide mobility ratio
(Dw/Dv) values (Figures 3 and S13 and Videos 7−14). Both
surface composition and shape had a clear effect on particle
mobility in vitreous fluid. In terms of surface composition, CA-
modified particles showed enhanced diffusion in the vitreous as
compared to U or A-modified variants, which can be explained
by negative interactions with anionic polysaccharides such as
hyaluronic acid. In terms of shape, tubular polymersomes were
clearly more mobile than spheres with ratio values at between
55 and 75% that of spheres. Due to the gel-like environment of
the vitreous, 100 nm-wide tubular shapes (as opposed to bulky
spheres) likely possessed enhanced diffusion due to their
ability to transverse the vitreal gel more effectively than
spheres. In line with this logic, worm-like micelles (having
significantly greater aspect ratio as compared to tubes) yielded
diffusion ratio values over threefold lower than those of tubes,
thus diffusing faster. These observations give additional insight
into the enhanced cellular uptake of tubes and worms
(particularly those with CA-modified surfaces) that can be
related to their enhanced mobility in vitreous, increasing the
degree of cell interactions in agreement with the literature.10
As a proof-of-principal and to highlight the ability of
nonspherical morphologies to enhance penetration of complex
biological barriers, fluorescently labeled CA-tubes were shown
to penetrate the inner limiting membrane (ILM) of the retina
(Figure S14). Even though absolute conclusions could not be
drawn from those images, the ability of elongated nanoparticles
to transpose such an interface highlights their value for further
exploration for a potential retinal application.
■ CONCLUSION
In conclusion, we demonstrated that nanoparticle morphology
is an important factor in the design of drug delivery systems
due to its impact on behavior such as cell uptake, drug release
kinetics, and diffusion in complex biological media. High
aspect ratio nanostructures (such as tubular polymersomes and
worm-like micelles) have great potential for further develop-
ment toward therapeutic applications (such as ocular therapy).
In combination with computational modeling, the use of such
morphologically diverse nanoparticles would deepen our
understanding of the role of parameters such as size, shape,
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Video in 3D of U-sphere nanoparticles uptaken by
ARPE-19 cells (MP4)
Video in 3D of A-sphere nanoparticles uptaken by
ARPE-19 cells (MP4)
Video in 3D of CA-sphere nanoparticles uptaken by
ARPE-19 cells (MP4)
Video in 3D of U-tube nanoparticles uptaken by ARPE-
19 cells (MP4)
Figure 3. Diffusion of diverse nanoparticle morphologies in vitreous. (A) Scheme for the preparation and sample measurement in an ex vivo eye
model. (B) Example of nanoparticle mobility trajectories in the ex vivo eye as measured using confocal microscopy and processed using Imaris
software. (C) Chart of Dw/Dv ratios for diverse particle morphologies.
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Video in 3D of A-tube nanoparticles uptaken by ARPE-
19 cells (MP4)
Video in 3D of CA-tube nanoparticles uptaken by
ARPE-19 cells (MP4)
Video of U-sphere nanoparticles mobility in ex vivo eye
(MP4)
Video of A-sphere nanoparticles mobility in ex vivo eye
(MP4)
Video of CA-sphere nanoparticles mobility in ex vivo eye
(MP4)
Video of U-tube nanoparticles mobility in ex vivo eye
(MP4)
Video of A-tube nanoparticles mobility in ex vivo eye
(MP4)
Video of CA-tube nanoparticles mobility in ex vivo eye
(MP4)
Video of U-worm nanoparticles mobility in ex vivo eye
(MP4)
Video of CA-worm nanoparticles mobility in ex vivo eye
(MP4)
Polymer synthesis and characterizations by NMR and
GPC, particles characterizations by DLS and CryoTEM,
cell uptake of particles by FACS, confocal imaging, 3D
experiments, drug loading and release experiments, and
particle mobility and permeation in ex vivo eye (PDF)
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